Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL-A167 Combined With Cisplatin and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT05294172Phase 3Active, not recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jun 2022
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tagitanlimab in nasopharyngeal carcinoma (NPC), sponsored by Kelun-Biotech. Started Jun 2022; status: active, not recruiting.
02
Drugs
tagitanlimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05294172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05294172.